The bet, if it pays off, could upend a corner of the global food industry worth tens of billions annually.
Verley, a Lyon-based biotech firm using microbes to brew dairy proteins without cows, closed an oversubscribed €32 million Series A round on February 24, 2026—a sum the company insists will bankroll its first major push into the United States by late this year. The capital injection, split between €25 million in equity and €7 million in non-dilutive support from France's Bpifrance, arrives at a moment when precision fermentation startups are either breaking through or quietly running out of runway.
For Verley—which until March 2025 went by the slightly more whimsical name Bon Vivant—the timing matters. The startup secured an FDA "no questions" letter in September 2025 for its beta-lactoglobulin whey protein, a regulatory nod that clears the way for commercial sales in a U.S. market increasingly hungry for alternative proteins. Whether American food manufacturers will actually buy in remains an open question.
Money, and Where It Came From
Paris-based venture firm Alven led the equity portion, joined by newcomers Blast and Bpifrance's French Tech Seed fund. Returning investors include Sofinnova Partners, Sparkfood, Captech Santé, and Founders Future. Jones Day advised Verley on the deal; Goodwin represented Alven.
It's worth noting this isn't Verley's first trip to the funding well. The company raised a €15 million seed round in October 2023 and a €4 million pre-seed back in April 2022. Add in €5 million in non-dilutive financing cobbled together from Bpifrance, BNP Paribas, CIC, and Société Générale in March 2024, and you get a startup that's pulled in roughly €56 million since launch. Not bad for a three-year-old operation brewing proteins in yeast.
The Science, in Brief
Verley's technology hinges on Aspergillus oryzae, a fungus better known in culinary circles for its role in fermenting soy sauce and sake. Here, the organism is engineered to churn out beta-lactoglobulin (BLG), one of the primary proteins found in cow's milk whey. The process, at least in theory, sidesteps the dairy farm entirely—no cows, no pasture, no methane emissions.
The company now offers four FermWhey variants targeting different food applications: Native (95-98% protein purity), Native 100 (high purity and acid-stable), MicroStab (engineered for UHT processing and acidic dairy drinks), and Gel (designed for spoonable products and cheese). According to product specs released in March 2025, Verley claims its Native formulation contains 11% more leucine than conventional whey protein isolates and 50% more than soy, though these figures have not been independently verified by third-party testing. Whether that translates to meaningful consumer preference—or premium pricing—remains untested at scale.
One wrinkle: BLG is still a milk allergen. The FDA's GRAS letter specifies use levels capped at 35% in nutrition bars and 25% in ready-to-drink performance beverages, and mandates allergen labeling. So much for a truly "animal-free" pitch to lactose-intolerant consumers.
The Founders
Co-founder and CEO Stéphane Mac Millan comes from McKinsey and a stint running Foodora France, the meal-delivery service. His co-founder, Hélène Briand, brings agronomy credentials and experience at Groupe Roullier, a French agricultural inputs conglomerate. It's a pairing that blends strategic consulting chops with technical know-how—classic startup founding team dynamics, though whether that mix translates to operational execution in a capital-intensive biotech sector is always the gamble.
The decision to rebrand from Bon Vivant to Verley in March 2025 was, according to the company, about shedding a French-specific identity ahead of international expansion. Fair enough, though one wonders if American buyers will find "Verley" any more intuitive.
The Competitive Landscape
Verley is hardly alone in the precision-fermented whey race. Vivici, a joint venture between DSM-Firmenich and New Zealand dairy giant Fonterra, is already in market. Israel's Imagindairy and Denmark's 21st.BIO are similarly positioned, each with their own microbial platforms and go-to-market strategies. The question isn't whether animal-free whey can be made at commercial scale—it's whether food manufacturers will pay for it when conventional whey remains abundant and, for now, cheaper.
Traditional whey prices have faced pressure recently, according to AgFunderNews reporting from February 2026, even as protein demand surges globally. That dynamic could work in Verley's favor if its production economics tighten and customers start valuing supply chain diversification or sustainability credentials. Or it could make the company's pitch that much harder if buyers balk at switching suppliers for a premium ingredient that consumers may not even notice.
What Happens Next
The immediate plan: ramp production capacity and finalize partnerships with unnamed U.S. customers for commercial deliveries before the end of 2026. Verley is also pursuing EU Novel Food approval in parallel, though no regulatory clearance has surfaced publicly as of this writing.
Whether the company hits those timelines—and whether American food brands actually incorporate fermented whey proteins at meaningful volumes—will determine if this €32 million bet turns into a sustainable business or another cautionary tale in the alt-protein space. For now, Verley has regulatory clearance, fresh capital, and a narrow window to prove the market exists.
The company declined to name its initial U.S. customers. That's standard practice in ingredient deals, but it also means the real test is still ahead.
